SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ: AZN) publicly traded securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), have until Friday, February 21, 2025 to seek appointment as lead plaintiff of the AstraZeneca class action lawsuit. Captioned Saleh v. AstraZeneca PLC, No. 24-cv-11021 (C.D. Cal.), the AstraZeneca class action lawsuit charges AstraZeneca and ...

Core Viewpoint - A class action securities lawsuit has been filed against AstraZeneca PLC, alleging securities fraud that adversely affected investors between February 23, 2022, and December 17, 2024 [1][2]. Group 1: Lawsuit Details - The complaint alleges that AstraZeneca engaged in insurance fraud in China, leading to heightened legal exposure and the detention of the AstraZeneca China President by law enforcement [2]. - It is claimed that AstraZeneca understated its legal risks, and the revelation of these issues could materially harm its business activities in China [2]. - The defendants' statements regarding AstraZeneca's business, operations, and prospects are alleged to be materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until February 21, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - AstraZeneca's antibody-drug conjugate, datopotamab deruxtecan (Datroway), has received FDA approval for treating a specific type of breast cancer, marking a significant milestone in the company's oncology portfolio [1][2]. Drug Approval and Market Potential - Datroway is approved for unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have undergone prior endocrine-based therapy and chemotherapy [1]. - The FDA's approval follows a similar approval in Japan, based on phase III TROPION-Breast01 study data, which demonstrated a 37% reduction in the risk of disease progression or death compared to standard chemotherapy [2]. - AstraZeneca anticipates Datroway could achieve peak annual sales of at least $5 billion, contributing to the company's goal of reaching $80 billion in annual revenues by 2030 [3]. Clinical Development and Future Prospects - Datroway is the second ADC developed in partnership with Daiichi Sankyo, with ongoing evaluations in various cancer indications, including breast and lung cancers [7][8]. - The companies are conducting extensive clinical trials, including seven late-stage programs for lung cancer and five for breast cancer [8]. - A priority review by the FDA is underway for Datroway to treat adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, with a decision expected in Q3 2025 [9][10]. Additional Developments - AstraZeneca's cancer drug Calquence has received an expanded label for first-line treatment of mantle cell lymphoma, now approved in combination with chemoimmunotherapy for previously untreated patients [11][12]. - The approval for Calquence is based on phase III ECHO study data, showing a 27% reduction in the risk of disease progression or death compared to chemoimmunotherapy alone [12].

Shareholders that Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky about Pending Class Action - AZN ...

Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN ...

AstraZeneca PLC Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm ...

Core Viewpoint - AstraZeneca PLC stockholders who have incurred losses are being encouraged to participate in a class action lawsuit led by Bronstein, Gewirtz and Grossman, LLC [1] Group 1 - The law firm Bronstein, Gewirtz and Grossman, LLC is announcing the opportunity for AstraZeneca stockholders to lead a class action lawsuit [1] - The announcement targets stockholders who have experienced financial losses related to their investments in AstraZeneca [1] - The firm is seeking to represent those affected by the alleged misconduct of AstraZeneca [1]

Core Viewpoint - The article highlights the importance for AstraZeneca PLC investors to seek legal counsel before a significant deadline related to a securities class action lawsuit initiated by Rosen Law Firm [1] Group 1 - The securities class action was first filed by Rosen Law Firm, indicating potential legal challenges for AstraZeneca PLC [1] - Investors are encouraged to act promptly to secure counsel, emphasizing the urgency of the situation [1] - The article suggests that there may be implications for AstraZeneca's stock performance depending on the outcome of the class action [1]

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of AstraZeneca PLC (AZN) Shareholders ...

Core Viewpoint - AstraZeneca PLC is facing a lawsuit for alleged violations of securities laws, prompting investors to contact Levi & Korsinsky to discuss their rights before February 21, 2025 [1] Group 1 - The lawsuit indicates potential legal challenges for AstraZeneca, which may impact investor confidence and stock performance [1] - Investors are encouraged to take action by reaching out to legal representatives to understand their rights and options regarding the lawsuit [1]